Mycoplasma pneumoniae Infections: Pathogenesis and Vaccine Development
- PMID: 33503845
- PMCID: PMC7911756
- DOI: 10.3390/pathogens10020119
Mycoplasma pneumoniae Infections: Pathogenesis and Vaccine Development
Abstract
Mycoplasma pneumoniae is a major causative agent of community-acquired pneumonia which can lead to both acute upper and lower respiratory tract inflammation, and extrapulmonary syndromes. Refractory pneumonia caused by M. pneumonia can be life-threatening, especially in infants and the elderly. Here, based on a comprehensive review of the scientific literature related to the respective area, we summarize the virulence factors of M. pneumoniae and the major pathogenic mechanisms mediated by the pathogen: adhesion to host cells, direct cytotoxicity against host cells, inflammatory response-induced immune injury, and immune evasion. The increasing rate of macrolide-resistant strains and the harmful side effects of other sensitive antibiotics (e.g., respiratory quinolones and tetracyclines) in young children make it difficult to treat, and increase the health risk or re-infections. Hence, there is an urgent need for development of an effective vaccine to prevent M. pneumoniae infections in children. Various types of M. pneumoniae vaccines have been reported, including whole-cell vaccines (inactivated and live-attenuated vaccines), subunit vaccines (involving M. pneumoniae protein P1, protein P30, protein P116 and CARDS toxin) and DNA vaccines. This narrative review summarizes the key pathogenic mechanisms underlying M. pneumoniae infection and highlights the relevant vaccines that have been developed and their reported effectiveness.
Keywords: DNA vaccines; Mycoplasma pneumonia; live vector vaccines; pathogenesis; subunit vaccines; virulence factors; whole-cell vaccine.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures


Similar articles
-
An attenuated multiple genetic mutant of Mycoplasma pneumoniae imparts good immuno-protection against M. pneumoniae pneumonia in BALB/c mice.Microb Pathog. 2022 Apr;165:105463. doi: 10.1016/j.micpath.2022.105463. Epub 2022 Mar 1. Microb Pathog. 2022. PMID: 35240287
-
Pathogenesis of Mycoplasma pneumoniae: An update.Indian J Med Microbiol. 2016 Jan-Mar;34(1):7-16. doi: 10.4103/0255-0857.174112. Indian J Med Microbiol. 2016. PMID: 26776112 Review.
-
Impact of viral coinfection and macrolide-resistant mycoplasma infection in children with refractory Mycoplasma pneumoniae pneumonia.BMC Infect Dis. 2020 Aug 26;20(1):633. doi: 10.1186/s12879-020-05356-1. BMC Infect Dis. 2020. PMID: 32847534 Free PMC article.
-
Reviewing advancement in Mycoplasma pneumoniae P30 adhesin protein provides insights for future diagnosis and treatment.Front Microbiol. 2024 Dec 13;15:1515291. doi: 10.3389/fmicb.2024.1515291. eCollection 2024. Front Microbiol. 2024. PMID: 39735188 Free PMC article. Review.
-
Insight into the Pathogenic Mechanism of Mycoplasma pneumoniae.Curr Microbiol. 2022 Dec 2;80(1):14. doi: 10.1007/s00284-022-03103-0. Curr Microbiol. 2022. PMID: 36459213 Free PMC article. Review.
Cited by
-
The Mycoplasma spp. 'Releasome': A New Concept for a Long-Known Phenomenon.Front Microbiol. 2022 Apr 15;13:853440. doi: 10.3389/fmicb.2022.853440. eCollection 2022. Front Microbiol. 2022. PMID: 35495700 Free PMC article. Review.
-
Ultrasensitive, Specific, and Rapid Detection of Mycoplasma pneumoniae Using the ERA/CRISPR-Cas12a Dual System.Front Microbiol. 2022 May 13;13:811768. doi: 10.3389/fmicb.2022.811768. eCollection 2022. Front Microbiol. 2022. PMID: 35633705 Free PMC article.
-
Research status and challenges of Mycoplasma pneumoniae pneumonia in children: A bibliometric and visualization analysis from 2011 to 2023.Medicine (Baltimore). 2024 Mar 15;103(11):e37521. doi: 10.1097/MD.0000000000037521. Medicine (Baltimore). 2024. PMID: 38489686 Free PMC article.
-
Predictive value of immune-related parameters in severe Mycoplasma pneumoniae pneumonia in children.Transl Pediatr. 2024 Sep 30;13(9):1521-1528. doi: 10.21037/tp-24-172. Epub 2024 Sep 13. Transl Pediatr. 2024. PMID: 39399713 Free PMC article.
-
Effectiveness of the six-step approach guided online training program to improve knowledge of Mycoplasma pneumoniae pneumonia among pediatricians: a pretest-posttest study.Transl Pediatr. 2024 May 31;13(5):760-769. doi: 10.21037/tp-24-53. Epub 2024 May 24. Transl Pediatr. 2024. PMID: 38840684 Free PMC article.
References
-
- Xu W., Guo L., Dong X., Li X., Zhou P., Ni Q., Zhou X.Y., Wagner B.L., Li L. Detection of viruses and Mycoplasma pneumoniae in hospitalized patients with severe acute respiratory infection in northern China, 2015–2016. Jpn. J. Infect. Dis. 2018;71:134–139. doi: 10.7883/yoken.JJID.2017.412. - DOI - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources